UNLABELLED: Portopulmonary hypertension affects up to 6% of patients with advanced liver disease, but the predictors and biologic mechanism for the development of this complication are unknown. We sought to determine the clinical risk factors for portopulmonary hypertension in patients with advanced liver disease. We performed a multicenter case-control study nested within a prospective cohort of patients with portal hypertension recruited from tertiary care centers. Cases had a mean pulmonary artery pressure > 25 mm Hg, pulmonary vascular resistance > 240 dynes x second x cm(-5), and pulmonary capillary wedge pressure < or = 15 mm Hg. Controls had a right ventricular systolic pressure < 40 mm Hg (if estimable) and normal right-sided cardiac morphology by transthoracic echocardiography. The study sample included 34 cases and 141 controls. Female sex was associated with a higher risk of portopulmonary hypertension than male sex (adjusted odds ratio = 2.90, 95% confidence interval 1.20-7.01, P = 0.018). Autoimmune hepatitis was associated with an increased risk (adjusted odds ratio = 4.02, 95% confidence interval 1.14-14.23, P = 0.031), and hepatitis C infection was associated with a decreased risk (adjusted odds ratio = 0.24, 95% confidence interval 0.09-0.65, P = 0.005) of portopulmonary hypertension. The severity of liver disease was not related to the risk of portopulmonary hypertension. CONCLUSION: Female sex and autoimmune hepatitis were associated with an increased risk of portopulmonary hypertension, whereas hepatitis C infection was associated with a decreased risk in patients with advanced liver disease. Hormonal and immunologic factors may therefore be integral to the development of portopulmonary hypertension.
UNLABELLED: Portopulmonary hypertension affects up to 6% of patients with advanced liver disease, but the predictors and biologic mechanism for the development of this complication are unknown. We sought to determine the clinical risk factors for portopulmonary hypertension in patients with advanced liver disease. We performed a multicenter case-control study nested within a prospective cohort of patients with portal hypertension recruited from tertiary care centers. Cases had a mean pulmonary artery pressure > 25 mm Hg, pulmonary vascular resistance > 240 dynes x second x cm(-5), and pulmonary capillary wedge pressure < or = 15 mm Hg. Controls had a right ventricular systolic pressure < 40 mm Hg (if estimable) and normal right-sided cardiac morphology by transthoracic echocardiography. The study sample included 34 cases and 141 controls. Female sex was associated with a higher risk of portopulmonary hypertension than male sex (adjusted odds ratio = 2.90, 95% confidence interval 1.20-7.01, P = 0.018). Autoimmune hepatitis was associated with an increased risk (adjusted odds ratio = 4.02, 95% confidence interval 1.14-14.23, P = 0.031), and hepatitis C infection was associated with a decreased risk (adjusted odds ratio = 0.24, 95% confidence interval 0.09-0.65, P = 0.005) of portopulmonary hypertension. The severity of liver disease was not related to the risk of portopulmonary hypertension. CONCLUSION: Female sex and autoimmune hepatitis were associated with an increased risk of portopulmonary hypertension, whereas hepatitis C infection was associated with a decreased risk in patients with advanced liver disease. Hormonal and immunologic factors may therefore be integral to the development of portopulmonary hypertension.
Authors: Michael J Krowka; Karen L Swanson; Robert P Frantz; Michael D McGoon; Russell H Wiesner Journal: Hepatology Date: 2006-12 Impact factor: 17.425
Authors: Philippe Herve; Jerome Le Pavec; Benjamin Sztrymf; Benoit Decante; Laurent Savale; Olivier Sitbon Journal: Best Pract Res Clin Gastroenterol Date: 2007 Impact factor: 3.043
Authors: Eric Hachulla; Virginie Gressin; Loïc Guillevin; Patrick Carpentier; Elisabeth Diot; Jean Sibilia; André Kahan; Jean Cabane; Camille Francès; David Launay; Luc Mouthon; Yannick Allanore; Kiet Phong Tiev; Pierre Clerson; Pascal de Groote; Marc Humbert Journal: Arthritis Rheum Date: 2005-12
Authors: N Sussman; V Kaza; N Barshes; R Stribling; J Goss; C O'Mahony; E Zhang; J Vierling; A Frost Journal: Am J Transplant Date: 2006-06-22 Impact factor: 8.086
Authors: Steven M Kawut; Darren B Taichman; Vivek N Ahya; Sandra Kaplan; Christine L Archer-Chicko; Stephen E Kimmel; Harold I Palevsky Journal: Liver Transpl Date: 2005-09 Impact factor: 5.799
Authors: Steven M Kawut; Evelyn M Horn; Ketevan K Berekashvili; Robert P Garofano; Rochelle L Goldsmith; Allison C Widlitz; Erika B Rosenzweig; Diane Kerstein; Robyn J Barst Journal: Am J Cardiol Date: 2005-01-15 Impact factor: 2.778
Authors: M M Hoeper; H J Seyfarth; G Hoeffken; H Wirtz; E Spiekerkoetter; M W Pletz; T Welte; M Halank Journal: Eur Respir J Date: 2007-07-25 Impact factor: 16.671
Authors: Kari E Roberts; Michael B Fallon; Michael J Krowka; Raymond L Benza; James A Knowles; David B Badesch; Robert S Brown; Darren B Taichman; James Trotter; Steven Zacks; Evelyn M Horn; Steven M Kawut Journal: Chest Date: 2009-01-13 Impact factor: 9.410
Authors: Kari E Roberts; Michael B Fallon; Michael J Krowka; Robert S Brown; James F Trotter; Inga Peter; Hocine Tighiouart; James A Knowles; Daniel Rabinowitz; Raymond L Benza; David B Badesch; Darren B Taichman; Evelyn M Horn; Steven Zacks; Neil Kaplowitz; Steven M Kawut Journal: Am J Respir Crit Care Med Date: 2009-02-12 Impact factor: 21.405